TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T45299	Tissue-type plasminogen activator	D07UWV	Argatroban	Approved	92722	C23H36N6O5S	508.6	C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C	Ki = 87800 nM	Poor binder
T45299	Tissue-type plasminogen activator	B03ZOI	3-Hydroxy-4-iodo-anthracene-2-carboxylic acid (4-guanidino-phenyl)-amide	Investigative	44304098	C22H17IN4O2	496.3	C1=CC=C2C=C3C(=CC2=C1)C=C(C(=C3I)O)C(=O)NC4=CC=C(C=C4)N=C(N)N	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B0CO7M	N-(5-Phenyl-isoquinolin-1-yl)-guanidine	Investigative	44339192	C16H14N4	262.31	C1=CC=C(C=C1)C2=CC=CC3=C2C=CN=C3N=C(N)N	Ki = 123900 nM	Poor binder
T45299	Tissue-type plasminogen activator	B0FN8O	2-Carboxyindole-based inhibitor 28	Investigative	10391881	C27H24ClN5O2S	518	C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3N2CC4=NOC(=C4)C5=CC=C(S5)Cl)C6=CC=NC=C6	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B0KAI3	5-[4-[3-(6-Chloro-2-naphthylsulfonyl)propanoyl]piperazino]imidazo[1,2-a]pyridine-2-methanol	Investigative	10391715	C25H25ClN4O4S	513	C1CN(CCN1C2=CC=CC3=NC(=CN32)CO)C(=O)CCS(=O)(=O)C4=CC5=C(C=C4)C=C(C=C5)Cl	Ki ~ 60000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B0KH8P	4-[(E)-(5-Oxo-2-phenyl-1,3-oxazol-4-ylidene)methyl]benzenecarboximidamide	Investigative	16220264	C17H13N3O2	291.3	C1=CC=C(C=C1)C2=N/C(=C/C3=CC=C(C=C3)C(=N)N)/C(=O)O2	IC50 = 68510 nM	Poor binder
T45299	Tissue-type plasminogen activator	B0O7EL	1-Guanidino-7-sulfonamidoisoquinoline 14	Investigative	16658357	C13H14ClN5O4S	371.8	C1=CC2=C(C=C1S(=O)(=O)NCCC(=O)O)C(=NC=C2Cl)N=C(N)N	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B0P7CL	Cyclic deriv. 35	Investigative	16658183	C16H18ClN5O4S	411.9	C1CCN([C@H](C1)C(=O)O)S(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B0R3BK	6-Fluoro-2-[2-hydroxy-3-((S)-3-methyl-cyclohexyloxy)-phenyl]-1H-benzoimidazole-5-carboxamidine	Investigative	136092211	C21H23FN4O2	382.4	C[C@H]1CCC[C@@H](C1)OC2=CC=CC(=C2O)C3=NC4=C(N3)C=C(C(=C4)C(=N)N)F	Ki = 150000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B12YBD	N-(4-Guanidino-phenyl)-2-hydroxy-5-methoxy-benzamide	Investigative	44304047	C15H16N4O3	300.31	COC1=CC(=C(C=C1)O)C(=O)NC2=CC=C(C=C2)N=C(N)N	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B13HLB	N-(4-Guanidino-phenyl)-2-hydroxy-4-methyl-benzamide	Investigative	44304006	C17H20N4O2	312.37	CC1=CC(=C(C=C1)C(=O)N(C)C2=CC=C(C=C2)N=C(N)N)OC	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B15ULK	Substituted glycine deriv. 16	Investigative	16658742	C13H14ClN5O4S	371.8	CN(CC(=O)O)S(=O)(=O)C1=CC2=C(C=C1)C(=CN=C2N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B1P8KG	2-Carboxyindole-based inhibitor 24	Investigative	23647194	C24H25ClN4O2S	469	CC(C)N1CC[C@H](C1)NC(=O)C2=CC3=CC=CC=C3N2CC4=NOC(=C4)C5=CC=C(S5)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B1S9XC	N-((1R,2S,5S)-2-(5-Chloro-1H-indole-2-carboxamido)-5-(dimethylcarbamoyl)cyclohexyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-C]pyridine-2-carboxamide	Investigative	9808346	C26H31ClN6O3S	543.1	CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C4=CC5=C(N4)C=CC(=C5)Cl)C(=O)N(C)C	Ki = 68200 nM	Poor binder
T45299	Tissue-type plasminogen activator	B27QTA	{(R)-2-[2-((S)-1-Formyl-4-guanidino-butylcarbamoyl)-azetidin-1-yl]-1-methyl-2-oxo-1-phenyl-ethyl}-carbamic acid tert-butyl ester	Investigative	10814863	C24H36N6O5	488.6	C[C@@](C1=CC=CC=C1)(C(=O)N2CC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O)NC(=O)OC(C)(C)C	IC50 = 120000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B27WSD	(2S)-N-Cyclopentyl-N-methyl-5-[4-(methylamino)phenyl]-2-[(4-propylphenyl)sulfonylamino]pent-4-ynamide	Investigative	10390481	C27H35N3O3S	481.7	CCCC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CC#CC2=CC=C(C=C2)NC)C(=O)N(C)C3CCCC3	Ki = 190000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B28LHJ	(17S,20R)-20-(Benzylsulfonylamino)-N-[(4-carbamimidoylphenyl)methyl]-3,10,19-trioxo-2,5,8,11,18-pentazatetracyclo[20.2.2.25,8.212,15]triaconta-1(25),12,14,22(26),23,27-hexaene-17-carboxamide;2,2,2-trifluoroacetic acid	Investigative	71720404	C43H48F3N9O8S	908	C1CN2CCN1CC(=O)NC3=CC=C(C[C@H](C(=O)N[C@@H](CC4=CC=C(C=C4)NC(=O)C2)C(=O)NCC5=CC=C(C=C5)C(=N)N)NS(=O)(=O)CC6=CC=CC=C6)C=C3.C(=O)(C(F)(F)F)O	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B28OHJ	Ethyl 1-(diphenoxyphosphoryl)-2-(4-guanidinophenyl)ethylcarbamate	Investigative	16718712	C24H27N4O5P	482.5	CCOC(=O)NC(CC1=CC=C(C=C1)N=C(N)N)P(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3	IC50 = 57000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B2KWI7	N-Isoquinolin-1-yl-guanidine	Investigative	18771297	C10H10N4	186.21	C1=CC=C2C(=C1)C=CN=C2N=C(N)N	Ki = 126200 nM	Poor binder
T45299	Tissue-type plasminogen activator	B2P6IQ	6-Fluoro-2-[2-hydroxy-3-(4-methyl-cyclohexyloxy)-phenyl]-1H-benzoimidazole-5-carboxamidine	Investigative	136092209	C21H23FN4O2	382.4	CC1CCC(CC1)OC2=CC=CC(=C2O)C3=NC4=C(N3)C=C(C(=C4)C(=N)N)F	Ki = 71000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B2R6WK	3-[(R)-3-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-2-(naphthalene-2-sulfonylamino)-3-oxo-propyl]-benzamidine	Investigative	10815545	C26H31N5O4S	509.6	C1CN(CCN1CCO)C(=O)[C@@H](CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3	Ki = 180000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B2TWQ0	N-(4-Chloro-isoquinolin-1-yl)-guanidine	Investigative	44339231	C10H9ClN4	220.66	C1=CC=C2C(=C1)C(=CN=C2N=C(N)N)Cl	Ki = 128500 nM	Poor binder
T45299	Tissue-type plasminogen activator	B30SGZ	6-Carbamimidoyl-naphthalene-2-carboxylic acid (3,5-dimethoxy-phenyl)-amide	Investigative	11450922	C20H19N3O3	349.4	COC1=CC(=CC(=C1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=N)N)OC	IC50 ~ 62000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B3K9LO	3-[(R)-3-(4-Formyl-piperazin-1-yl)-2-(naphthalene-2-sulfonylamino)-3-oxo-propyl]-benzamidine	Investigative	10624997	C25H27N5O4S	493.6	C1CN(CCN1C=O)C(=O)[C@@H](CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3	Ki = 110000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B3LRT9	N-[2'-(Aminosulfonyl)-4-biphenylyl]-Nalpha-(3-amidinobenzoyl)-D-phenylglycinamide	Investigative	44330879	C28H25N5O4S	527.6	C1=CC=C(C=C1)[C@H](C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3S(=O)(=O)N)NC(=O)C4=CC=CC(=C4)C(=N)N	IC50 ~ 180000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B3M5YL	3-(6-Chloronaphthalen-2-yl)sulfonyl-N-methyl-N-[1-(2-methylpyridin-4-yl)piperidin-4-yl]propanamide	Investigative	10117027	C25H28ClN3O3S	486	CC1=NC=CC(=C1)N2CCC(CC2)N(C)C(=O)CCS(=O)(=O)C3=CC4=C(C=C3)C=C(C=C4)Cl	Ki = 67000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B3W0VJ	2-(4-Diethylamino-2-hydroxy-phenyl)-1H-benzoimidazole-5-carboxamidine	Investigative	135544579	C18H21N5O	323.4	CCN(CC)C1=CC(=C(C=C1)C2=NC3=C(N2)C=C(C=C3)C(=N)N)O	Ki = 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B3XE7D	8-(Pyrimidin-2-ylamino)-6-((E)-styryl)-naphthalene-2-carboxamidine	Investigative	44392403	C23H19N5	365.4	C1=CC=C(C=C1)/C=C/C2=CC(=C3C=C(C=CC3=C2)C(=N)N)NC4=NC=CC=N4	Ki ~ 50000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B4A5KU	4-Bromo-3-hydroxy-anthracene-2-carboxylic acid (4-guanidino-phenyl)-amide	Investigative	44304099	C22H17BrN4O2	449.3	C1=CC=C2C=C3C(=CC2=C1)C=C(C(=C3Br)O)C(=O)NC4=CC=C(C=C4)N=C(N)N	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B4AQ2J	Substituted glycine deriv. 30	Investigative	16658031	C16H18ClN5O5S	427.9	C1COCCC1(C(=O)O)NS(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B4CQ1W	2-[3-(Phenylethynyl)-5-chloro-2-pyridinyl]guanidine	Investigative	44298525	C14H11ClN4	270.72	C1=CC=C(C=C1)C#CC2=C(N=CC(=C2)Cl)N=C(N)N	Ki = 65900 nM	Poor binder
T45299	Tissue-type plasminogen activator	B4EIL5	Diphenyl 1-(N-benzyloxycarbonylamino)-1-(4-amidinophenyl)propanephosphonate	Investigative	24748791	C30H30N3O5P	543.5	C1=CC=C(C=C1)COC(=O)NC(CCC2=CC=C(C=C2)C(=N)N)P(=O)(OC3=CC=CC=C3)OC4=CC=CC=C4	IC50 = 68000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B4EZ5H	N-(5-Bromo-isoquinolin-1-yl)-guanidine	Investigative	44339233	C10H9BrN4	265.11	C1=CC2=C(C=CN=C2N=C(N)N)C(=C1)Br	Ki = 140100 nM	Poor binder
T45299	Tissue-type plasminogen activator	B4UZ2R	6-Fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine	Investigative	445847	C18H19FN4O2	342.4	CC(C)COC1=CC=CC(=C1O)C2=NC3=C(N2)C=C(C(=C3)C(=N)N)F	Ki = 61000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B54PRQ	Benzyl 2-[[6-amino-3-chloro-5-[(Z)-N'-hydroxycarbamimidoyl]pyrazin-2-yl]amino]acetate	Investigative	136266885	C14H15ClN6O3	350.76	C1=CC=C(C=C1)COC(=O)CNC2=NC(=C(N=C2Cl)/C(=N/O)/N)N	IC50 = 200000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B5DCY2	1-(2-Amino-3,3-dicyclohexyl-propionyl)-pyrrolidine-2-carboxylic acid (4-amino-cyclohexylmethyl)-amide	Investigative	10367012	C27H48N4O2	460.7	C1CCC(CC1)C(C2CCCCC2)[C@H](C(=O)N3CCC[C@H]3C(=O)NCC4CCC(CC4)N)N	Ki = 137000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B5JE7T	N-(4-Guanidino-phenyl)-2-hydroxy-3-methyl-benzamide	Investigative	44304353	C15H16N4O2	284.31	CC1=C(C(=CC=C1)C(=O)NC2=CC=C(C=C2)N=C(N)N)O	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B5PJX1	2-(3-Methoxy-2-hydroxyphenyl)-1H-benzimidazole-5-carboxamidine	Investigative	135427245	C15H14N4O2	282.3	COC1=CC=CC(=C1O)C2=NC3=C(N2)C=C(C=C3)C(=N)N	Ki = 69000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B5VJ7P	(2S)-N-[(2S)-5-(Diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-phenyl-2-[(2,2,2-trifluoroacetyl)amino]propanoyl]azetidine-2-carboxamide	Investigative	10791027	C21H27F3N6O4	484.5	C[C@@](C1=CC=CC=C1)(C(=O)N2CC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O)NC(=O)C(F)(F)F	IC50 = 130000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B64SUE	1-Guanidino-7-sulfonamidoisoquinoline 12	Investigative	16658356	C17H14ClN5O4S	419.8	C1=CC(=CC(=C1)NS(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl)C(=O)O	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B67YGB	2-(1-(3-(6-Chloronaphthalen-2-ylsulfonyl)propanoyl)piperidin-4-yl)-5-methyl-1H-imidazo[1,5-c]imidazol-3(2H)-one	Investigative	9935746	C24H25ClN4O4S	501	CC1=NC=C2N1C(=O)N(C2)C3CCN(CC3)C(=O)CCS(=O)(=O)C4=CC5=C(C=C4)C=C(C=C5)Cl	Ki ~ 60000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B6MQT3	N-(4-Amidinophenyl)-2-hydroxy-3-phenylbenzamide	Investigative	44303804	C20H17N3O2	331.4	C1=CC=C(C=C1)C2=C(C(=CC=C2)C(=O)NC3=CC=C(C=C3)C(=N)N)O	Ki = 53000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B6VSZ1	3-Hydroxy-4-methoxy-anthracene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide	Investigative	44303935	C22H19N5O3	401.4	COC1=C(C(=CC2=CC3=CC=CC=C3C=C21)C(=O)NC4=CN=C(C=C4)N=C(N)N)O	Ki = 150000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B78ZBK	N-(4-Guanidino-phenyl)-2-hydroxy-benzamide	Investigative	44303733	C14H14N4O2	270.29	C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)N=C(N)N)O	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B7R5UJ	1-{[5-(5-Chloro-2-thienyl)isoxazol-3-YL]methyl}-N-(1-isopropylpiperidin-4-YL)-1H-indole-2-carboxamide	Investigative	6540265	C25H27ClN4O2S	483	CC(C)N1CCC(CC1)NC(=O)C2=CC3=CC=CC=C3N2CC4=NOC(=C4)C5=CC=C(S5)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B7W3KD	2-Biphenyl-3-yl-1H-indole-5-carboxamidine	Investigative	10946869	C21H17N3	311.4	C1=CC=C(C=C1)C2=CC(=CC=C2)C3=CC4=C(N3)C=CC(=C4)C(=N)N	Ki = 138000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B7ZB9U	2-[3-[(E)-2-Cyclohexylethenyl]-5-chloro-2-pyridinyl]guanidine	Investigative	44298523	C14H19ClN4	278.78	C1CCC(CC1)/C=C/C2=C(N=CC(=C2)Cl)N=C(N)N	Ki = 71500 nM	Poor binder
T45299	Tissue-type plasminogen activator	B87OAE	Diphenyl N-(benzyloxycarbonyl)amino(4-amidinophenyl)methanephosphonate	Investigative	9827867	C28H26N3O5P	515.5	C1=CC=C(C=C1)COC(=O)NC(C2=CC=C(C=C2)C(=N)N)P(=O)(OC3=CC=CC=C3)OC4=CC=CC=C4	IC50 = 66000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B8AFI9	4-Chloro-N-(4-guanidino-phenyl)-2-hydroxy-benzamide	Investigative	44304046	C14H13ClN4O2	304.73	C1=CC(=CC=C1NC(=O)C2=C(C=C(C=C2)Cl)O)N=C(N)N	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B8M4EP	5-Bromo-N-(4-guanidino-phenyl)-2-hydroxy-benzamide	Investigative	44303719	C14H13BrN4O2	349.18	C1=CC(=CC=C1NC(=O)C2=C(C=CC(=C2)Br)O)N=C(N)N	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B8VYZ0	Benzyl 2-[[6-amino-3-chloro-5-(diaminomethylidenecarbamoyl)pyrazin-2-yl]amino]acetate	Investigative	57404503	C15H16ClN7O3	377.78	C1=CC=C(C=C1)COC(=O)CNC2=NC(=C(N=C2Cl)C(=O)N=C(N)N)N	IC50 ~ 190000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B9EMP4	2-[[4-Chloro-1-(diaminomethylideneamino)isoquinolin-7-yl]sulfonylamino]benzoic Acid	Investigative	11419694	C17H14ClN5O4S	419.8	C1=CC=C(C(=C1)C(=O)O)NS(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B9GZ5S	7-Methoxy-8-[1-(methylsulfonyl)-1H-pyrazol-4-YL]naphthalene-2-carboximidamide	Investigative	5289529	C16H16N4O3S	344.4	COC1=C(C2=C(C=CC(=C2)C(=N)N)C=C1)C3=CN(N=C3)S(=O)(=O)C	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B9VGY7	3-Hydroxy-4-methoxy-anthracene-2-carboxylic acid (4-guanidino-phenyl)-amide	Investigative	44304097	C23H20N4O3	400.4	COC1=C(C(=CC2=CC3=CC=CC=C3C=C21)C(=O)NC4=CC=C(C=C4)N=C(N)N)O	Ki = 181000 nM	Poor binder
T45299	Tissue-type plasminogen activator	B9WVZ2	2-[3-[(E)-Styryl]-5-chloro-2-pyridinyl]guanidine	Investigative	44298524	C14H13ClN4	272.73	C1=CC=C(C=C1)/C=C/C2=C(N=CC(=C2)Cl)N=C(N)N	Ki = 53800 nM	Poor binder
T45299	Tissue-type plasminogen activator	BA6QC9	N-(4-Carbamimidoyl-phenyl)-2-hydroxy-5-nitro-benzamide	Investigative	44303808	C14H12N4O4	300.27	C1=CC(=CC=C1C(=N)N)NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])O	Ki = 94000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BAM0E8	6-Fluoro-2-[2-hydroxy-3-((S)-2-methyl-cyclohexyloxy)-phenyl]-1H-benzoimidazole-5-carboxamidine	Investigative	447540	C21H23FN4O2	382.4	C[C@@H]1CCCC[C@@H]1OC2=CC=CC(=C2O)C3=NC4=C(N3)C=C(C(=C4)C(=N)N)F	Ki = 58000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BB16XW	2-{5-[Amino(iminio)methyl]-1H-benzimidazol-2-YL}benzenolate	Investigative	1506	C14H12N4O	252.27	C1=CC=C(C(=C1)C2=NC3=C(N2)C=C(C=C3)C(=N)N)O	Ki = 75000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BB1FV3	3-[(E)-2-(5-Chloro-2-guanidino-pyridin-3-yl)-vinyl]-benzoic acid	Investigative	9948854	C15H13ClN4O2	316.74	C1=CC(=CC(=C1)C(=O)O)/C=C/C2=C(N=CC(=C2)Cl)N=C(N)N	Ki = 52000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BB7C6R	(S)-1-(9-Hydroxy-9H-3-aza-fluorene-9-carbonyl)-pyrrolidine-2-carboxylic acid 2-aminomethyl-5-chloro-benzylamide	Investigative	11317532	C26H25ClN4O3	477	C1C[C@H](N(C1)C(=O)C2(C3=C(C=NC=C3)C4=CC=CC=C42)O)C(=O)NCC5=C(C=CC(=C5)Cl)CN	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BBY1C6	4-Ethoxy-N-(4-guanidino-phenyl)-2-hydroxy-benzamide	Investigative	44303824	C16H18N4O3	314.34	CCOC1=CC(=C(C=C1)C(=O)NC2=CC=C(C=C2)N=C(N)N)O	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BBYR96	2-Carboxyindole-based inhibitor 33	Investigative	23647198	C25H20ClN5O2S	490	C1C(CN1C2=CC=NC=C2)NC(=O)C3=CC4=CC=CC=C4N3CC5=NOC(=C5)C6=CC=C(S6)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BCAL64	3-Hydroxy-anthracene-2-carboxylic acid (4-guanidino-phenyl)-amide	Investigative	44304104	C22H18N4O2	370.4	C1=CC=C2C=C3C=C(C(=CC3=CC2=C1)C(=O)NC4=CC=C(C=C4)N=C(N)N)O	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BDT3P2	Substituted glycine deriv. 17	Investigative	16658407	C18H16ClN5O4S	433.9	C1=CC=C(C=C1)N(CC(=O)O)S(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BF6XK1	2-(5-Nitro-2-hydroxyphenyl)-1H-benzimidazole-5-carboxamidine	Investigative	135407736	C14H11N5O3	297.27	C1=CC2=C(C=C1C(=N)N)NC(=N2)C3=C(C=CC(=C3)[N+](=O)[O-])O	Ki = 56000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BG8FM0	1-{2-[(4-Chlorophenyl)amino]-2-oxoethyl}-N-(1-isopropylpiperidin-4-YL)-1H-indole-2-carboxamide	Investigative	6540268	C25H29ClN4O2	453	CC(C)N1CCC(CC1)NC(=O)C2=CC3=CC=CC=C3N2CC(=O)NC4=CC=C(C=C4)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BGI97R	2-(2-Hydroxy-3-ethoxyphenyl)-6-chloro-1H-benzimidazole-5-carboxamidine	Investigative	136092208	C16H15ClN4O2	330.77	CCOC1=CC=CC(=C1O)C2=NC3=C(N2)C=C(C(=C3)C(=N)N)Cl	Ki ~ 75000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BGQ9K3	6-Carbamimidoyl-naphthalene-2-carboxylic acid (4-carbamoyl-phenyl)-amide	Investigative	11244460	C19H16N4O2	332.4	C1=CC(=CC=C1C(=O)N)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=N)N	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BH3QG6	2-Carboxyindole-based inhibitor 13	Investigative	20801121	C25H25ClN4O2S	481	C1CC1N2CCC(CC2)NC(=O)C3=CC4=CC=CC=C4N3CC5=NOC(=C5)C6=CC=C(S6)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BHL7S1	6-Carbamimidoyl-naphthalene-2-carboxylic acid (4-ethyl-phenyl)-amide	Investigative	11347670	C20H19N3O	317.4	CCC1=CC=C(C=C1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=N)N	Ki = 83900 nM	Poor binder
T45299	Tissue-type plasminogen activator	BHS98V	2-(2-Hydroxy-3-ethoxyphenyl)-6-fluoro-1H-benzimidazole-5-carboxamidine	Investigative	136092214	C16H15FN4O2	314.31	CCOC1=CC=CC(=C1O)C2=NC3=C(N2)C=C(C(=C3)C(=N)N)F	Ki ~ 75000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BI1R2Q	Benzyl 2-[(6-amino-5-carbamimidoyl-3-chloropyrazin-2-yl)amino]acetate	Investigative	57404502	C14H15ClN6O2	334.76	C1=CC=C(C=C1)COC(=O)CNC2=NC(=C(N=C2Cl)C(=N)N)N	IC50 = 200000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BI5U8S	6-(2-Phenylcyclopropyl)naphthalene-2-carboximidamide	Investigative	21707065	C20H18N2	286.4	C1C(C1C2=CC3=C(C=C2)C=C(C=C3)C(=N)N)C4=CC=CC=C4	Ki = 69110 nM	Poor binder
T45299	Tissue-type plasminogen activator	BI6HN2	2-Carboxyindole-based inhibitor 7	Investigative	20801139	C23H23ClN4O2S	455	CN1CCC(CC1)NC(=O)C2=CC3=CC=CC=C3N2CC4=NOC(=C4)C5=CC=C(S5)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BI97QF	Chembl2332610	Investigative	71716976	C64H93N17O16S3	1452.7	C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSCC2=CC3=CC(=C2)CSC[C@@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@@H](CSC3)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N1)CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)O)CC7=CC=C(C=C7)O	Ki ~ 120000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BIY84V	2-(2-Hydroxy-biphenyl-3-yl)-3-methyl-3H-benzoimidazole-5-carboxamidine	Investigative	135535997	C21H18N4O	342.4	CN1C2=C(C=CC(=C2)C(=N)N)N=C1C3=CC=CC(=C3O)C4=CC=CC=C4	Ki = 150000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BJ3RV5	1H-Indole-1-acetamide,N-(5-chloro-2-pyridinyl)-2-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-	Investigative	10095455	C24H28ClN5O2	454	CC(C)N1CCC(CC1)NC(=O)C2=CC3=CC=CC=C3N2CC(=O)NC4=NC=C(C=C4)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BJ5GN1	3-Chloro-N-(4-guanidino-phenyl)-2-hydroxy-benzamide	Investigative	44304192	C14H13ClN4O2	304.73	C1=CC(=C(C(=C1)Cl)O)C(=O)NC2=CC=C(C=C2)N=C(N)N	Ki = 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BK3BX5	2-(5-Methyl-2-hydroxyphenyl)-1H-benzimidazole-5-carboxamidine	Investigative	135443730	C15H14N4O	266.3	CC1=CC(=C(C=C1)O)C2=NC3=C(N2)C=C(C=C3)C(=N)N	Ki = 113000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BK5SO7	Substituted glycine deriv. 29	Investigative	9802514	C17H20ClN5O4S	425.9	C1CCC(CC1)(C(=O)O)NS(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BK75XF	Naphthalene-2-carboximidamide	Investigative	193409	C11H10N2	170.21	C1=CC=C2C=C(C=CC2=C1)C(=N)N	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BKS48Q	N-[2-(3-Amidinophenoxy)ethyl]-2'-sulfamoylbiphenyl-4-carboxamide	Investigative	9954812	C22H22N4O4S	438.5	C1=CC=C(C(=C1)C2=CC=C(C=C2)C(=O)NCCOC3=CC=CC(=C3)C(=N)N)S(=O)(=O)N	IC50 = 109000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BL0O2Q	N-Butyl-3-[[4-(diaminomethylideneamino)phenyl]methylamino]imidazo[1,2-a]pyridine-7-carboxamide	Investigative	127041472	C20H25N7O	379.5	CCCCNC(=O)C1=CC2=NC=C(N2C=C1)NCC3=CC=C(C=C3)N=C(N)N	IC50 ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BL7R2B	3-[(R)-3-(4-Methanesulfonyl-piperazin-1-yl)-2-(naphthalene-2-sulfonylamino)-3-oxo-propyl]-benzamidine	Investigative	10816339	C25H29N5O5S2	543.7	CS(=O)(=O)N1CCN(CC1)C(=O)[C@@H](CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3	Ki = 190000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BLQ3J7	N-(7-Phenyl-isoquinolin-1-yl)-guanidine	Investigative	44339270	C16H14N4	262.31	C1=CC=C(C=C1)C2=CC3=C(C=C2)C=CN=C3N=C(N)N	Ki = 123900 nM	Poor binder
T45299	Tissue-type plasminogen activator	BM4CJ5	N-(6-Carbamimidoyl-naphthalen-2-yl)-benzamide	Investigative	11149953	C18H12N2O	272.3	C1=CC=C(C=C1)C(=O)NC2=CC3=C(C=C2)C=C(C=C3)C#N	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BM6ND8	Chembl2332604	Investigative	71716975	C59H82N16O15S3	1351.6	C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSCC2=CC3=CC(=C2)CSC[C@@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@@H](CSC3)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N1)CCCN=C(N)N)NC(=O)CN)C(=O)NCC(=O)O)CC7=CC=C(C=C7)O	Ki ~ 120000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BND4O9	(2S)-N-[(2S)-5-(Diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-phenyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]azetidine-2-carboxamide	Investigative	10791461	C22H29F3N6O4	498.5	CC[C@@](C1=CC=CC=C1)(C(=O)N2CC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O)NC(=O)C(F)(F)F	IC50 = 62000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BNV7U9	2-(5-Methoxy-2-hydroxyphenyl)-1H-benzimidazole-5-carboxamidine	Investigative	1503	C15H14N4O2	282.3	COC1=CC(=C(C=C1)O)C2=NC3=C(N2)C=C(C=C3)C(=N)N	Ki = 63000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BO9SZ8	2-(1-(3-(6-Chloronaphthalen-2-ylsulfonyl)propanoyl)piperidin-4-yl)-5-(hydroxymethyl)-1H-imidazo[1,5-c]imidazol-3(2H)-one	Investigative	10324263	C24H25ClN4O5S	517	C1CN(CCC1N2CC3=CN=C(N3C2=O)CO)C(=O)CCS(=O)(=O)C4=CC5=C(C=C4)C=C(C=C5)Cl	Ki ~ 60000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BOI71W	N-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-N-(cyclopentylmethyl)glycine	Investigative	16658408	C18H22ClN5O4S	439.9	C1CCC(C1)CN(CC(=O)O)S(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BP4G7N	Cyclic deriv. 34	Investigative	16658181	C15H16ClN5O4S	397.8	C1C[C@H](N(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl)C(=O)O	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BP6EM8	N-Methyl-2-[[[[(2-naphthyl)sulfonyl]amino]acetyl]amino]-3-[3-(diaminomethyl)phenyl]propanamide	Investigative	44367355	C23H27N5O4S	469.6	CNC(=O)C(CC1=CC(=CC=C1)C(N)N)NC(=O)CNS(=O)(=O)C2=CC3=CC=CC=C3C=C2	Ki = 69000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BP81YN	2-(3-Methyl-2-hydroxyphenyl)-1H-benzimidazole-5-carboxamidine	Investigative	135501618	C15H14N4O	266.3	CC1=C(C(=CC=C1)C2=NC3=C(N2)C=C(C=C3)C(=N)N)O	Ki = 69000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BPC7D8	2-Carboxyindole 17	Investigative	20801160	C26H28ClN3OS	466	CC(C)N1CCC(CC1)NC(=O)C2=CC3=CC=CC=C3N2CC4=CC5=C(S4)C=C(C=C5)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BPD92J	N-(4-Guanidino-phenyl)-2-hydroxy-5-methyl-benzamide	Investigative	44303839	C15H16N4O2	284.31	CC1=CC(=C(C=C1)O)C(=O)NC2=CC=C(C=C2)N=C(N)N	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BQHU17	N-(4-Bromo-isoquinolin-1-yl)-guanidine	Investigative	44339232	C10H9BrN4	265.11	C1=CC=C2C(=C1)C(=CN=C2N=C(N)N)Br	Ki = 159200 nM	Poor binder
T45299	Tissue-type plasminogen activator	BR1ZG9	2-Hydroxy-biphenyl-3-carboxylic acid (4-guanidino-phenyl)-amide	Investigative	44304105	C20H18N4O2	346.4	C1=CC=C(C=C1)C2=C(C(=CC=C2)C(=O)NC3=CC=C(C=C3)N=C(N)N)O	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BR56DV	N-[1-(3-Diaminomethyl-benzyl)-2-oxo-2-piperidin-1-yl-ethyl]-4-methyl-benzenesulfonamide	Investigative	44367444	C22H30N4O3S	430.6	CC1=CC=C(C=C1)S(=O)(=O)NC(CC2=CC(=CC=C2)C(N)N)C(=O)N3CCCCC3	Ki = 120000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BRXD81	Diphenyl 1-(benzoylamino)-2-(4-guanidinophenyl)-ethanephosphonate	Investigative	16718807	C28H27N4O4P	514.5	C1=CC=C(C=C1)C(=O)NC(CC2=CC=C(C=C2)N=C(N)N)P(=O)(OC3=CC=CC=C3)OC4=CC=CC=C4	IC50 = 125000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BS65JA	Substituted glycine deriv. 23	Investigative	16657879	C15H18ClN5O4S	399.9	CC(C)[C@@H](C(=O)O)NS(=O)(=O)C1=CC2=C(C=C1)C(=CN=C2N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BSAX59	6-Carbamimidoyl-N-[1-(2-methylpropyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]naphthalene-2-carboxamide	Investigative	11188793	C25H28N4O	400.5	CC(C)CC1C2=C(CCN1)C=CC(=C2)NC(=O)C3=CC4=C(C=C3)C=C(C=C4)C(=N)N	Ki ~ 50000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BSCM59	6-[N-(4-(Aminomethyl)phenyl)carbamyl]-2-naphthalenecarboxamidine	Investigative	447733	C19H18N4O	318.4	C1=CC(=CC=C1CN)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=N)N	Ki = 58400 nM	Poor binder
T45299	Tissue-type plasminogen activator	BSE63D	1-({4-Chloro-1-[(Diaminomethylidene)amino]isoquinolin-7-Yl}sulfonyl)-D-Proline	Investigative	9843775	C15H16ClN5O4S	397.8	C1C[C@@H](N(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl)C(=O)O	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BTYL37	2-Carboxyindole-based inhibitor 31	Investigative	22394409	C27H24ClN5O2S	518	C1CN(CCC1NC2=CC=NC=C2)C(=O)C3=CC4=CC=CC=C4N3CC5=NOC(=C5)C6=CC=C(S6)Cl	Ki = 64010 nM	Poor binder
T45299	Tissue-type plasminogen activator	BU38EA	Cycloleucine deriv. 43	Investigative	16658290	C18H23ClN6O4S	454.9	C1CCC(C1)(C(=O)NCCO)NS(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki = 108000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BUM8R9	(3S)-N-[2'-(Aminosulfonyl)-4-biphenylyl]-2-(3-amidinobenzoyl)-1,2,3,4-tetrahydroisoquinoline-3alpha-carboxamide	Investigative	44331194	C30H27N5O4S	553.6	C1[C@H](N(CC2=CC=CC=C21)C(=O)C3=CC=CC(=C3)C(=N)N)C(=O)NC4=CC=C(C=C4)C5=CC=CC=C5S(=O)(=O)N	IC50 = 180000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BV45PY	(S)-2-(1-(3-(6-Chloronaphthalen-2-ylsulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)-5-methyl-1H-imidazo[1,5-c]imidazol-3(2H)-one	Investigative	46196561	C24H25ClN4O5S	517	CC1=NC=C2N1C(=O)N(C2)C3CCN(CC3)C(=O)[C@@H](CS(=O)(=O)C4=CC5=C(C=C4)C=C(C=C5)Cl)O	Ki ~ 60000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BW27LG	(2S)-N-[(4-Aminocyclohexyl)methyl]-1-(3,3-dicyclohexylpropanoyl)pyrrolidine-2-carboxamide;hydrochloride	Investigative	45261772	C27H48ClN3O2	482.1	C1CCC(CC1)C(CC(=O)N2CCC[C@H]2C(=O)NCC3CCC(CC3)N)C4CCCCC4.Cl	Ki = 84000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BW6SN2	Substituted glycine deriv. 24	Investigative	16657882	C16H20ClN5O4S	413.9	CC(C)(C)[C@H](C(=O)O)NS(=O)(=O)C1=CC2=C(C=C1)C(=CN=C2N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BW9UX0	(20S)-20-Benzyl-25-chloro-1,4,13,18,21,23-hexazatricyclo[20.3.1.06,11]hexacosa-6,8,10,22,24-pentaene-3,26-dione	Investigative	135528485	C27H33ClN6O2	509	C1CCNCC2=CC=CC=C2CNC(=O)CN3C(=CN=C(C3=O)N[C@H](CNC1)CC4=CC=CC=C4)Cl	Ki = 165000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BWIE23	Substituted glycine deriv. 25	Investigative	16657950	C20H20ClN5O4S	461.9	C[C@@H](C(=O)O)N(CC1=CC=CC=C1)S(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BX4HS5	2-Carboxyindole-based inhibitor 8	Investigative	10412365	C24H25ClN4O2S	469	CCN1CCC(CC1)NC(=O)C2=CC3=CC=CC=C3N2CC4=NOC(=C4)C5=CC=C(S5)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BX9G8U	N-[1-(Piperidinocarbonyl)-2-[4-(diaminomethyl)phenyl]ethyl]-2-[(2-naphthylsulfonyl)amino]acetamide	Investigative	44367382	C27H33N5O4S	523.6	C1CCN(CC1)C(=O)C(CC2=CC=C(C=C2)C(N)N)NC(=O)CNS(=O)(=O)C3=CC4=CC=CC=C4C=C3	Ki = 70000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BY1V3F	Substituted glycine deriv. 27	Investigative	9930716	C15H16ClN5O4S	397.8	C1CC(C1)(C(=O)O)NS(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BY24QF	N-(7-Bromo-isoquinolin-1-yl)-guanidine	Investigative	44339277	C10H9BrN4	265.11	C1=CC(=CC2=C1C=CN=C2N=C(N)N)Br	Ki = 95100 nM	Poor binder
T45299	Tissue-type plasminogen activator	BY95OX	2-[3-[(E)-4-Methoxystyryl]-5-chloro-2-pyridinyl]guanidine	Investigative	44298507	C15H15ClN4O	302.76	COC1=CC=C(C=C1)/C=C/C2=C(N=CC(=C2)Cl)N=C(N)N	Ki = 60100 nM	Poor binder
T45299	Tissue-type plasminogen activator	BZ56DU	(2S)-N-Cyclopentyl-N-methyl-5-[4-(methylamino)phenyl]-2-(5,6,7,8-tetrahydronaphthalen-2-ylsulfonylamino)pent-4-ynamide	Investigative	10345602	C28H35N3O3S	493.7	CNC1=CC=C(C=C1)C#CC[C@@H](C(=O)N(C)C2CCCC2)NS(=O)(=O)C3=CC4=C(CCCC4)C=C3	Ki = 200000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BZ7W8H	Substituted glycine deriv. 18	Investigative	16658745	C19H18ClN5O4S	447.9	C1=CC=C(C=C1)CN(CC(=O)O)S(=O)(=O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	BZSH38	N-(4-Guanidino-phenyl)-2-hydroxy-5-nitro-benzamide	Investigative	44303721	C14H13N5O4	315.28	C1=CC(=CC=C1NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])O)N=C(N)N	Ki ~ 95000 nM	Poor binder
T45299	Tissue-type plasminogen activator	D06CJP	4-chloro-1-guanidino-7-isoquinolinesulphonamide	Investigative	16658353	C10H10ClN5O2S	299.74	C1=CC2=C(C=C1S(=O)(=O)N)C(=NC=C2Cl)N=C(N)N	Ki ~ 100000 nM	Poor binder
T45299	Tissue-type plasminogen activator	D0A8WP	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	Investigative	447732	C18H15N3O	289.3	C1=CC=C(C=C1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=N)N	IC50 = 125000 nM	Poor binder